Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX) from a sell rating to a hold rating in a report issued on Sunday.

Several other analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. BTIG Research set a $73.00 price objective on Protagonist Therapeutics in a research report on Monday, March 3rd. BMO Capital Markets increased their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Truist Financial boosted their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. lifted their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.44.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $56.37 on Friday. The firm has a market cap of $3.49 billion, a P/E ratio of 21.19 and a beta of 2.25. Protagonist Therapeutics has a 1 year low of $30.67 and a 1 year high of $60.60. The stock has a 50-day simple moving average of $45.95 and a 200-day simple moving average of $43.19.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $28.32 million during the quarter, compared to the consensus estimate of $30.44 million. On average, equities research analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares of the company’s stock, valued at approximately $4,676,140.08. The trade was a 26.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Asif Ali sold 1,756 shares of the firm’s stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the completion of the transaction, the chief financial officer now directly owns 61,065 shares in the company, valued at $2,808,990. This trade represents a 2.80% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,270 shares of company stock worth $1,998,626 over the last 90 days. 4.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Protagonist Therapeutics

A number of institutional investors have recently bought and sold shares of PTGX. Bank of Montreal Can grew its holdings in Protagonist Therapeutics by 4.5% during the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock valued at $241,000 after purchasing an additional 270 shares during the period. GF Fund Management CO. LTD. increased its stake in Protagonist Therapeutics by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company’s stock valued at $74,000 after buying an additional 275 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in Protagonist Therapeutics by 1.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock worth $779,000 after acquiring an additional 278 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock worth $1,112,000 after purchasing an additional 300 shares in the last quarter. Finally, Hsbc Holdings PLC raised its position in Protagonist Therapeutics by 4.1% during the first quarter. Hsbc Holdings PLC now owns 8,458 shares of the company’s stock worth $405,000 after acquiring an additional 330 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.